Genetic or pharmacological inhibition of either TLR2 or TLR4 have been shown to reduce MI size and prevent adverse LV remodeling following AMI (Arslan et al., 2010; Oyama et al., 2004; Shimamoto et al., 2006; Shishido et al., 2003; Timmers et al., 2008), making these particular TLRs potential therapeutic targets for cardioprotection (see Section 3). This evidence concerns the gene TLR4 and myocardial infarction.